Medicare Stands by Coverage Decision for Alzheimer’s Therapies

The Medicare agency on Wednesday denied a request to revisit its decision to only cover Biogen’s Alzheimer’s drug Aduhelm and others like it for patients in clinical trial settings.

The announcement is a blow to patients groups like the Alzheimer’s Association, which submitted a formal request in December to the Centers for Medicare and Medicaid Services asking the agency to reconsider its 2022 decision for covering FDA-approved monoclonal antibodies directed against amyloid for the treatment of Alzheimer’s disease.

“After careful review of the request and supporting documentation, we are making this decision because, as of the date of this letter, ...